Go to content

Publications

460 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. GVS advice GLP-1 receptor agonists extension further conditions

    The National Health Care Institute advises the Minister to extend the reimbursement conditions for dulaglutide, exenatide, ...

    Report | 16-05-2022

  2. GVS advice to not include pitolisant (Ozawade®)

    The National Health Care Institute has completed its assessment whether pitolisant (Ozawade®) can be included in the Medicine ...

    Report | 10-05-2022

  3. Package advice vitamin D

    The National Health Care Institute recommends that all colecalciferol-containing medicinal products and calcifediol be removed ...

    Report | 09-05-2022

  4. Package advice on zanubrutinib (Brukinsa®) for the treatment of Waldenström macroglobulinaemia (WM)

    The National Health Care Institute advises the Minister to include zanubrutinib (Brukinsa®) in the basic health insurance package ...

    Report | 27-04-2022

  5. GVS advice on dabigatran etexilate (Pradaxa®) capsules extension further conditions

    The National Health Care Institute advises the Minister to amend List 2 of the GVS to extend the reimbursement of dabigatran ...

    Report | 25-04-2022

  6. International strategic agenda 2022-2023 National Health Care Institute

    The international strategic agenda 2022-2023 describes the international activities of the National Health Care Institute ...

    Publication | 21-04-2022

  7. GVS advice ivermectin (Stromectol®)

    The National Health Care Institute advises the Minister to include ivermectin (Stromectol®) in List 1B and List 2 of the GVS. ...

    Report | 20-04-2022

  8. GVS advice avacopan (Tavneos®)

    The National Health Care Institute advises the Minister not to include avacopan (Tavneos®) in the GVS. Avacopan is indicated for ...

    Report | 20-04-2022

  9. GVS advice on finerenon (Kerendia®)

    The National Health Care Institute advises the Minister to include finerenon (Kerendia®) in List 1B of the GVS. Finerenon is ...

    Report | 04-04-2022

  10. GVS advice extension further conditions for dapagliflozin (Forxiga®)

    The National Health Care Institute has completed its assessment whether the further conditions for dapagliflozin (Forxiga®) could ...

    Report | 28-03-2022

Go to